Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Oct 24, 2020 12:05pm
91 Views
Post# 31776627

RE:Interesting Chart Pattern Shows.......

RE:Interesting Chart Pattern Shows.......The share price rose sharply in mid August after the McMaser Covid research update and Q2, it then over corrected to low 60's (wiping out gains from these 2 great fundamental catalysts), has consolidated between 60 - 70 and has just broken out of the trading range this week.

The catalyst is the use of increased NRC grant towards the large scale industrial mfg of PGX Y-BG at the PGX demo plant to generate product for human clinical trials. I for one would have expected such an annoucment to be met with a flurry of investors piling in. 

A muted response from the market so far, that is another sign of in-efficient markets in the nano-cap stock universe.  One requisite of efficient markets is dissemination of information and investors reacting accordingly. Absent here for sure.






<< Previous
Bullboard Posts
Next >>